A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors

Authors
Jeroen de Filette1, Corina Emilia Andreescu1, Filip Cools2, Bert Bravenboer1, Brigitte Velkeniers1

Affiliations
1 Department of Endocrinology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium
2 Department of Neonatology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium

Key words
hypophysitis, thyroiditis, CTLA-4, PD-1, PD-L1

received 11.06.2018
accepted 22.01.2019

Bibliography
DOI https://doi.org/10.1055/a-0843-3366
Horm Metab Res 2019; 51: 145–156
© Georg Thieme Verlag KG Stuttgart · New York
ISSN 0018-5043

Correspondence
Jeroen de Filette
Department of Endocrinology
Universitair Ziekenhuis Brussel
Vrije Universiteit Brussel
Laarbeeklaan 101
1090 Brussels
Belgium
Tel.: +32 2 477 60 01, Fax: +32 2 477 68 00
jdefilet@vub.ac.be

Supplementary Material for this article is available online at http://www.thieme-connect.de/products.

ABSTRACT
Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death 1 (PD-1), or its ligand (PD-L1) have become the mainstay for advanced malignancies. The incidence of endocrine adverse events provoked by these immune checkpoint inhibitors (ICI) is based on data from randomized controlled trials, which have their drawbacks. PubMed was searched through August 22nd, 2017, by 2 reviewers independently (J.d.F. and C.E.A.). Early phase I/II, phase III experimental trials, prospective and retrospective observational studies were included. The weighted incidence and risk ratio were estimated for hypophysitis, primary thyroid disease, primary adrenal insufficiency, and diabetes mellitus. Their management is discussed in a systematic review. A total of 101 studies involving 19 922 patients were included. Ipilimumab-treated patients experienced hypophysitis in 5.6 % (95 % CI, 3.9–8.1), which was higher than nivolumab (0.5 %; 95 % CI, 0.2–1.2) and pembrolizumab (1.1 %; 95 % CI, 0.5–2.6). PD-1/PD-L1 inhibitors had a higher incidence of thyroid dysfunction – particularly hypothyroidism (nivolumab, 8.0 %; 95 % CI, 6.4–9.8; pembrolizumab, 8.5 %; 95 % CI, 7.5–9.7; PD-L1, 5.5 %; 95 % CI, 4.4–6.8; ipilimumab, 3.8 %; 95 % CI, 2.6–5.5). Combination therapy was associated with a high incidence of hypothyroidism (10.2–16.4 %), hyperthyroidism (9.4–10.4 %), hypophysitis (8.8–10.5 %), and primary adrenal insufficiency (5.2–7.6 %). Diabetes mellitus and primary adrenal insufficiency were less frequent findings on monotherapy. Our meta-analysis shows a high incidence of endocrine adverse events provoked by single agent checkpoint blockade, further reinforced by combined treatment.

Introduction
Immune checkpoint inhibitors (ICI) are revolutionizing the management of advanced malignancies. The importance of this new generation of cancer therapy through immune modulation will only expand in the near future, given their recent extended approval [1]. These novel antibodies release the brakes of the immune system and potentiate antitumor immune responses through the inhibition of receptors on immune and cancer cells such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) or programmed cell death 1 (PD-1) and its ligand (PD-L1), whose function is to maintain self-tolerance [2]. Their side effects are equally fascinating as immune-related adverse events (irAE) have been described in almost all organs including the endocrine system. The anti-CTLA-4 agent ipilimumab is associated with the otherwise rare phenomenon of hypophysitis, while PD-1 inhibitors nivolumab and pembrolizumab often provoke primary thyroid dysfunction [3]. Notwithstanding, cases of primary adrenal insufficiency, fulminant diabetes mellitus, and hypoparathyroidism associated with checkpoint blockade have also been reported. The aim of the present study is to perform a systematic review and meta-analysis of immune checkpoint inhibitors...
and endocrine side effects, including their incidence, evaluation, and management.

Materials and Methods

Literature search

The PubMed database was searched through August 22nd, 2017, for relevant articles on the subject of endocrinopathies and ICI, by 2 reviewers independently (J.d.F. and C.E.A.). Search terms were included for the various endocrinopathies, adverse events and the currently available ICI: ‘ipilimumab’, ‘tremelimumab’, ‘nivolumab’, ‘pembrolizumab’, ‘atezolizumab’, ‘avelumab’ and ‘durvalumab’. These were combined with the Boolean logical operators AND/OR. The authors also checked recently published literature [3–7] and identified 2 additional studies. (Table 1, 2)

Study selection

Early phase I/II, phase III experimental trials, and prospective as well as retrospective observational studies were included. Study subjects had to be adults with any type of advanced, metastatic, or unresectable malignancy. Studies with regimens combining ICI with radiotherapy, cell vaccines, small molecule inhibitors or immunotherapy with IL-2 or interferon were omitted. Language was restricted to English or French. The investigators used the title and abstract for manuscript selection. Articles were categorized as follows: Clinical Study, Case Report, Review (of endocrine adverse events), Systematic Review or Meta-Analysis, Mechanism (of checkpoint blockade toxicity), Basic or Translational Research, Combination Therapy, Economic or Health-Care, Language, Pediatric, Off label. After initial selection, full texts were reviewed and further excluded if no endocrine adverse events were reported or if the safety data were inadequate. Duplicates or studies on the same population were identified through their trial registry number and excluded as well. Any discrepancies were discussed by all authors and resolved by consensus. Supplemental (Table 1S) provides an overview of all included studies [8–108].

Data analysis and extraction

The following elements were extracted from each included study: author and year of publication, study design, median follow-up time, treatment and placebo/chemotherapy arms, dosing and frequency of drug administration, endocrine adverse events (hypothyroidism, hyperthyroidism, thyroiditis, hypophysitis, primary adrenal insufficiency, and diabetes mellitus), trial registration number, and trial name. When available, supplementary data and appendices were also methodically explored.

Statistical analysis

For each study, the incidence of a specific endocrine adverse event was calculated by dividing the number of observed events by the total number of patients that were followed-up during the study period. A meta-analysis of incidence estimates was performed using an inverse variance method to weigh the studies. Summary estimates of incidence are reported with their 95% confidence interval (CI). For randomized controlled trials, a relative risk and 95% CI were calculated using the number of observed adverse events and the total number of patients in each group. If possible, relative risks from individual trials for the same adverse event were combined in a meta-analysis. Heterogeneity was assessed using the Q and I² statistics. The random-effects model was a priori selected based on the expected study heterogeneity. All analyses were performed with Comprehensive Meta-Analysis v3.0 (Biostat, Inc.).

Results

Study characteristics

Our search identified a total of 1169 articles, of which 959 were excluded based on title and abstract. Of the 210 full texts that were reviewed, 101 were finally included (Fig. 1). These included 7 phase II, 1 phase II/III, 17 phase III randomized trials, 64 prospective, and 12 retrospective studies. Within the 101 included articles, a total of 152 study arms were identified. The main tumor types were melanoma (69/152, 45%), non-small cell lung carcinoma (31/152, 20%), and renal cell carcinoma (11/152, 7%). A total of 19922 patients were analyzed (ipilimumab, n = 4430; tremelimumab, n = 1171; nivolumab, n = 3317; pembrolizumab, n = 4485; avelumab, n = 998; durvalumab, n = 316; pembrolizumab, n = 191; combination, n = 1078; placebo/chemotherapy, n = 3936). The regimens were classified as monotherapy with anti-CTLA-4 (41/152, 27%), anti-PD-1 (68/152, 45%), anti-PD-L1 (8/152, 5%), combination of anti-CTLA-4 with anti-PD-1 (13/152, 9%) or anti-PD-L1 (3/152, 2%), and placebo/chemotherapy (19/152, 13%).

Incidence of hypophysitis

The CTLA-4 inhibitor ipilimumab had a 5.6% (95% CI, 3.9–8.1) pooled estimated incidence of hypophysitis vs. 1.8% (95% CI, 1.1–2.9) for tremelimumab. Nivolumab and pembrolizumab had a lower incidence at 0.5% (95% CI, 0.2–1.2) and 1.1% (95% CI, 0.5–2.6), respectively. The highest estimated incidence was noted on combination therapy, ranging from 8.8% (95% CI, 6.2–12.4) to 10.5% (95% CI, 6.5–16.4). No data on hypophysitis were available for anti-PD-L1 agents. Compared to patients not receiving immunotherapy, ipilimumab-treated patients had a higher risk of developing hypophysitis (RR, 9.26; 95% CI, 0.51–169.66; p = 0.134). This was lower for nivolumab (RR, 2.06; 95% CI, 0.22–19.68; p = 0.531) and for pembrolizumab (RR, 2.89; 95% CI, 0.46–18.27; p = 0.259). These results were, however, not statistically different.

Incidence of primary thyroid disease

Checkpoint blockade with PD-1 or PD-L1 inhibitors was particularly associated with primary thyroid dysfunction. Hypothyroidism was most frequent, followed by hyperthyroidism and thyroiditis. The summary estimated incidence of hypothyroidism was 8.0% (95% CI, 6.4–9.8) for nivolumab, 8.5% (95% CI, 7.5–9.7) for pembrolizumab, 6.0% (95% CI, 4.2–8.4) for atezolizumab, 5.5% (95% CI, 3.5–8.7) for avelumab, and 4.7% (95% CI, 2.5–8.8) for durvalumab. Ipilimumab had a lower estimated incidence of 3.8% (95% CI, 2.6–5.5) while clear data on tremelimumab were missing. Regardless, one study reported up to 5.2% of thyroid disorders on tremelimumab [41]. Combination therapy had the highest estimated incidence of hypothyroidism with 10.2% (95% CI, 5.6–17.9) for durvalumab with tremelimumab, 15.1% (95% CI, 10.6–21.8) for...
<table>
<thead>
<tr>
<th></th>
<th>Hypothyroidism</th>
<th>Hyperthyroidism</th>
<th>Thyroiditis</th>
<th>Hypophysitis</th>
<th>PAI</th>
<th>DM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Target</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total patients</td>
<td>Analyzed patients</td>
<td>Summary incidence</td>
<td>Analyzed patients</td>
<td>Summary incidence</td>
<td>Analyzed patients</td>
</tr>
<tr>
<td>CTLA-4</td>
<td>Ipilimumab</td>
<td>4430</td>
<td>3614 (82 %)</td>
<td>3.8 (2.6–5.5)</td>
<td>147 (48 %)</td>
<td>1.4 (0.8–2.4)</td>
</tr>
<tr>
<td></td>
<td>Tremelimumab</td>
<td>1171</td>
<td>N/A</td>
<td>up to 5.2 %</td>
<td>N/A</td>
<td>up to 5.2 %</td>
</tr>
<tr>
<td>PD-1</td>
<td>Nivolumab</td>
<td>3317</td>
<td>3317 (100 %)</td>
<td>8.0 (6.4–9.8)</td>
<td>1710 (52 %)</td>
<td>2.8 (2.1–3.8)</td>
</tr>
<tr>
<td></td>
<td>Pembrolizumab</td>
<td>4485</td>
<td>4461 (99 %)</td>
<td>8.5 (7.5–9.7)</td>
<td>3757 (84 %)</td>
<td>3.7 (2.8–4.7)</td>
</tr>
<tr>
<td>PD-L1</td>
<td>Atezolizumab</td>
<td>998</td>
<td>998 (100 %)</td>
<td>6.0 (4.2–8.4)</td>
<td>3757 (84 %)</td>
<td>3.7 (2.8–4.7)</td>
</tr>
<tr>
<td></td>
<td>Avelumab</td>
<td>316</td>
<td>316 (100 %)</td>
<td>5.5 (3.5–8.7)</td>
<td>88 (28 %)</td>
<td>2.3 (0.6–8.6)</td>
</tr>
<tr>
<td></td>
<td>Durvalumab</td>
<td>191</td>
<td>191 (100 %)</td>
<td>4.7 (2.5–8.8)</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>Combined</td>
<td>816</td>
<td>739 (91 %)</td>
<td>16.4 (11.7–22.5)</td>
<td>520 (64 %)</td>
<td>9.4 (7.1–12.3)</td>
</tr>
<tr>
<td></td>
<td>Ipilimumab +</td>
<td>163</td>
<td>163 (100 %)</td>
<td>15.1 (10.6–21.8)</td>
<td>163 (100 %)</td>
<td>10.4 (6.6–16.1)</td>
</tr>
<tr>
<td></td>
<td>Nivolumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pembrolizumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Durvalumab +</td>
<td>99</td>
<td>99 (100 %)</td>
<td>10.2 (5.6–17.9)</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>Tremelimumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| The number of analyzed patients (%) is also reported. Clear data on tremelimumab were missing; * p for heterogeneity <0.10; † Ribas et al. [41] reported up to 5.2 % thyroid disorders; DM: Diabetes mellitus; N/A: Not applicable; NR: Not reported; PAI: Primary adrenal insufficiency.
Table 2 Summary of relative risk for endocrine adverse events.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Hypothyroidism % (95 % CI)</th>
<th>p-value</th>
<th>Hyperthyroidism % (95 % CI)</th>
<th>p-value</th>
<th>Thyroiditis % (95 % CI)</th>
<th>p-Value</th>
<th>Hypophysitis % (95 % CI)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ipilimumab vs. placebo/chemo</td>
<td>6.51 (3.37–12.58)</td>
<td>&lt;0.001</td>
<td>6.83 (0.81–57.83)</td>
<td>0.078</td>
<td>5.08 (0.25–105.29)</td>
<td>0.293</td>
<td>9.26 (0.51–169.66)</td>
<td>0.134</td>
</tr>
<tr>
<td>Nivolumab vs. placebo/chemo</td>
<td>11.19 (4.31–29.08)</td>
<td>&lt;0.001</td>
<td>4.20 (1.12–15.84)</td>
<td>0.034</td>
<td>2.56 (0.28–23.08)</td>
<td>0.402</td>
<td>2.06 (0.22–19.68)</td>
<td>0.531</td>
</tr>
<tr>
<td>Pembrolizumab vs. placebo/chemo</td>
<td>7.41 (4.06–13.52)</td>
<td>&lt;0.001</td>
<td>8.52 (3.66–19.84)</td>
<td>&lt;0.001</td>
<td>6.56 (0.80–53.61)</td>
<td>0.079</td>
<td>2.89 (0.46–18.27)</td>
<td>0.259</td>
</tr>
</tbody>
</table>

Selected Articles

- n=1169 Articles
- n=210 Articles
- n=101 Included Articles

Excluded Studies (n=959)
- Case Report
- Review
- Systematic Review or Meta-Analysis
- Mechanism of Toxicity
- Basic or Translational Research
- Combination Therapy
- Economic or Health-Care
- Language
- Pediatric
- Off-Topic

Excluded Studies (n=109)
- No Endocrine-Related AE
- Inadequate Safety Data
- Sequential Therapy
- Duplicate / Update

Fig. 1 Flow chart of study selection.

Ipilimumab with pembrolizumab and 16.4 % (95 % CI, 11.7–22.5) for ipilimumab with nivolumab. Compared to placebo/chemotherapy, the risk of hypothyroidism was significantly increased by all immunotherapies. The PD-1 inhibitor nivolumab (RR, 11.19; 95 % CI, 4.31–29.08; p<0.001) had a higher risk than pembrolizumab (RR, 7.41; 95 % CI, 4.06–13.52; p<0.001) or ipilimumab (RR, 6.51; 95 % CI, 3.37–12.58; p<0.001).

Predictions for hyperthyroidism were lower with a pooled incidence of 2.8 % (95 % CI, 2.1–3.8) for nivolumab, 3.7 % (95 % CI, 2.8–4.7) for pembrolizumab, 2.3 % (95 % CI, 0.6–8.6) for avelumab, and 1.4 % (95 % CI, 0.8–2.4) for ipilimumab. No data were available for atezolizumab and durvalumab. For combination therapy, the estimated incidence was 9.4 % (95 % CI, 7.1–12.3) for ipilimumab with nivolumab and 10.4 % (95 % CI, 6.6–16.1) for ipilimumab with pembrolizumab. As compared to placebo/chemotherapy, the risk of developing hyperthyroidism increased with nivolumab (RR, 4.20; 95 % CI, 1.12–15.84; p=0.034), pembrolizumab (RR, 8.52; 95 % CI, 3.66–19.84, p<0.001), and ipilimumab (RR, 6.83; 95 % CI, 0.81–57.83; p=0.078), although the latter was not significant.

Few data on thyroiditis were available. Estimations ranged from 1.6 % (95 % CI, 0.2–0.2) for nivolumab, 2.3 % (95 % CI, 1.2–4.6) for pembrolizumab, 2.1 % (95 % CI, 1.1–4.1) for ipilimumab, 3.8 % (95 % CI, 1.2–10.7) for avelumab, 1.3 % (95 % CI, 0.7–2.9) for nivolumab, 1.0 % (95 % CI, 0.2–3.4) for pembrolizumab, and 1.0 % (95 % CI, 0.2–2.5) for avelumab. No data were available for atezolizumab and durvalumab. For combination therapy, the estimated incidence was 7.0 % (95 % CI, 4.7–10.4) for ipilimumab with pembrolizumab and 8.3 % (95 % CI, 5.4–12.8) for ipilimumab with nivolumab. As compared to placebo/chemotherapy, the risk of developing thyroiditis increased with pembrolizumab (RR, 6.56; 95 % CI, 3.37–12.58; p<0.001) and nivolumab (RR, 4.20; 95 % CI, 1.12–15.84; p=0.034), although the latter was not significant.

Few data on hypophysitis were available. Estimations ranged from 0.7 % (95 % CI, 0.1–0.2) for nivolumab, 1.1 % (95 % CI, 0.5–2.4) for pembrolizumab, 1.0 % (95 % CI, 0.3–3.0) for avelumab, 1.0 % (95 % CI, 0.3–2.8) for nivolumab, 0.9 % (95 % CI, 0.3–2.4) for pembrolizumab, and 0.9 % (95 % CI, 0.3–2.5) for ipilimumab. No data were available for atezolizumab and durvalumab. For combination therapy, the estimated incidence was 1.8 % (95 % CI, 1.1–3.0) for ipilimumab with pembrolizumab and 1.8 % (95 % CI, 1.1–3.0) for ipilimumab with nivolumab. As compared to placebo/chemotherapy, the risk of developing hypophysitis increased with Pembrolizumab (RR, 8.52; 95 % CI, 3.66–19.84, p<0.001), and ipilimumab (RR, 6.83; 95 % CI, 0.81–57.83; p=0.078), although the latter was not significant.

Few data on hyperparathyroidism were available. Estimations ranged from 0.7 % (95 % CI, 0.1–0.2) for nivolumab, 1.1 % (95 % CI, 0.5–2.4) for pembrolizumab, 1.0 % (95 % CI, 0.3–3.0) for avelumab, 1.0 % (95 % CI, 0.3–2.8) for nivolumab, 0.9 % (95 % CI, 0.3–2.4) for pembrolizumab, and 0.9 % (95 % CI, 0.3–2.5) for ipilimumab. No data were available for atezolizumab and durvalumab. For combination therapy, the estimated incidence was 1.8 % (95 % CI, 1.1–3.0) for ipilimumab with pembrolizumab and 1.8 % (95 % CI, 1.1–3.0) for ipilimumab with nivolumab. As compared to placebo/chemotherapy, the risk of developing hyperparathyroidism increased with Pembrolizumab (RR, 8.52; 95 % CI, 3.66–19.84, p<0.001), and ipilimumab (RR, 6.83; 95 % CI, 0.81–57.83; p=0.078), although the latter was not significant.

Few data on parathyroiditis were available. Estimations ranged from 0.7 % (95 % CI, 0.1–0.2) for nivolumab, 1.1 % (95 % CI, 0.5–2.4) for pembrolizumab, 1.0 % (95 % CI, 0.3–3.0) for avelumab, 1.0 % (95 % CI, 0.3–2.8) for nivolumab, 0.9 % (95 % CI, 0.3–2.4) for pembrolizumab, and 0.9 % (95 % CI, 0.3–2.5) for ipilimumab. No data were available for atezolizumab and durvalumab. For combination therapy, the estimated incidence was 1.8 % (95 % CI, 1.1–3.0) for ipilimumab with pembrolizumab and 1.8 % (95 % CI, 1.1–3.0) for ipilimumab with nivolumab. As compared to placebo/chemotherapy, the risk of developing parathyroiditis increased with Pembrolizumab (RR, 8.52; 95 % CI, 3.66–19.84, p<0.001), and ipilimumab (RR, 6.83; 95 % CI, 0.81–57.83; p=0.078), although the latter was not significant.
Incidence of diabetes mellitus and primary adrenal insufficiency

Primary adrenal insufficiency had a predicted incidence of 1.4 % (95 % CI, 0.9–2.2) on ipilimumab, 1.3 % (95 % CI, 0.7–2.4) on tremelimumab, 2.0 % (95 % CI, 0.9–4.3) on nivolumab, and 0.8 % (95 % CI, 0.3–2.0) on pembrolizumab monotherapy. For combination therapy, estimations ranged from 5.2 % (95 % CI, 2.9–9.2) to 7.6 % (95 % CI, 1.2–36.8) for ipilimumab with nivolumab, nivolumab, or pembrolizumab, respectively.

Diabetes mellitus was mainly PD-1/PD-L1 related without cases observed on CTLA-4 therapy. The incidence was 2.0 % (95 % CI, 0.7–5.8) for nivolumab and 0.4 % (95 % CI, 0.2–1.3) for pembrolizumab. No further analyses were performed due to the rarity of these side effects.

Discussion

Our meta-analysis shows a high incidence of all-grade endocrine adverse events related to immune checkpoint therapy, which is further enhanced by combined treatment. The highest incidence of hypophysitis on monotherapy is noted on anti-CTLA-4 therapy with ipilimumab (but not with tremelimumab) although hypophysitis also develops during PD-1 blockade. The incidence of hypothyroidism on monotherapy is highest for PD-1 inhibitors, followed by PD-L1 and CTLA-4 blockade. Hypothyroidism and thyroiditis occur less frequently. Primary adrenal insufficiency and diabetes mellitus are less frequent, with no cases of diabetes mellitus reported on anti-CTLA-4 therapy. Combined ICI shows a remarkably higher incidence of hypothyroidism, hyperthyroidism, hypophysitis, and primary adrenal insufficiency.

Hypophysitis

Our analysis indicates an higher incidence of all-grade hypophysitis in patients treated with ipilimumab. Anti-CTLA-4-induced hypophysitis usually occurs after 4 to 10 weeks of treatment (usually after the third infusion). In one report, hypophysitis was more frequent among patients receiving a higher dose of ipilimumab (10 mg/kg) with a 2-fold risk increase compared to patients treated with lower dose (3 mg/kg) [8]. Hypophysitis was more frequent among older and male patients [18, 25]. Anti-PD-1 or PD-L1 treatment rarely induced hypophysitis or hypopituitarism. These findings extend the data of previous reviews [6, 8, 109–111]. Hypophysitis may be life-threatening due to the abrupt onset of central adrenal failure. The initial presentation is indolent and includes symptoms such as headache and fatigue. Hormonal and radiological evaluation of the pituitary should be performed. The pituitary is often diffusely enlarged in the acute phase, with or without stalk thickening. Homogeneous or heterogeneous pituitary gland enhancement is possible. This is followed by a gradual decrease in size of the pituitary with partial or complete loss of pituitary function [25, 27, 112]. Hence, normal imaging of the pituitary does not exclude its diagnosis [27]. Corticotropic, thyrotropic and gonadotropic functions are mostly affected, but long term failure of the corticotropic axis is paramount [10, 25, 112]. High-dose glucocorticoids are proposed for those with mass effect symptoms, such as severe headache or visual-field disturbance [27, 113, 114]. Their role in the prevention of secondary adrenal failure has, however, been challenged and it is possible that physiological corticosteroid substitution suffices [18, 25, 112]. The potential benefit of high-dose glucocorticoid treatment should be balanced against the loss of efficacy resulting from the anti-cancer immunotherapy, although this issue is controversial. Why ACTH, TSH, and gonadotropin cells are particularly vulnerable to destruction with anti-CTLA-4 mAb is not fully elucidated. The expression of CTLA-4 on ACTH- and TSH-secreting cells has been implicated through immunohistochemistry [115, 116]. Radiological mimicry with lymphocytic hypophysitis favors the hypothesis of a lymphocytic destruction of the pituitary [27] as a result of T cell–mediated cytotoxicity, but an anti-pituitary antibody mediated process cannot be excluded. Iwama et al. found that all 7 patients with hypophysitis developed antibodies recognizing predominantly TSH- (7/7), FSH- (5/7), and ACTH-secreting (3/7) cells [115]. The diagnostic accuracy of these pituitary antibodies is not yet known. An autopsy study suggests that administration of CTLA-4 blocking antibodies to patients who express high levels of pituitary CTLA-4 antigen causes a necrotizing form of hypophysitis through type II (IgG dependent) and type IV (T-cell dependent) immune mechanisms [116]. The difference in incidence between ipilimumab (IgG1) and tremelimumab (IgG2) is probably due to their different immunological subclasses. In humans, polymorphisms in the CTLA4 gene confer increased susceptibility to a variety of autoimmune diseases, including Hashimoto’s thyroiditis, type 1 diabetes mellitus, and Addison’s disease [117, 118]. This polymorphism has not been analyzed in patients developing hypophysitis on CTLA-4 blockade. Some data associate the endocrine and other immune-related adverse events to a better outcome of anti-cancer immunotherapy [25]. In one study, ipilimumab 10 mg/kg resulted in significantly longer overall survival against ipilimumab 3 mg/kg but with increased treatment-related adverse events including hypophysitis [111]. In summary, patients who receive immune checkpoint inhibitors, particularly anti-CTLA-4 therapy, should be carefully evaluated to detect pituitary-related side effects. In case of hypophysitis, adequate hormone replacement therapy should be initiated. Failure of the corticotropic axis is usually permanent and requires continuous glucocorticoid substitution therapy, while failure of thyrotropic and gonadotropic axes may be transient.

Thyroid dysfunction

Checkpoint blockade with PD-1 or PD-L1 inhibitors is particularly associated with primary thyroid dysfunction. The spectrum of thyroid side effects includes primary hypo-, hyperthyroidism, and painless thyroiditis. The authors define painless thyroiditis as thyrotoxicosis followed by euthyroidism or hypothyroidism, with negative TRAb, reduced or absent tracer uptake on technetium scan and/or increased 18 Fluorodeoxyglucose uptake on positron emission tomography (18FDG-PET). The authors define hypothyroidism as a suppressed TSH with an elevated fT4 and/or fT3 level, and hypothyroidism as an elevated TSH with a decreased fT4 level. Importantly, a preceding phase
of hyperthyroidism cannot be excluded in case of hypothyroidism, unless thyroid function tests were systematically followed. Painless thyroiditis can occur early-on, within the first weeks of checkpoint blockade therapy [83, 119, 120]. The initial phase of thyroiditis (suppressed TSH and high FT4) evolves within 3–6 weeks to hypothyroidism (high TSH and low FT4) [75, 83, 119, 120]. Symptoms of thyroiditis are rarely severe. The underlying process is likely to be a destructive, inflammatory thyroiditis. Thyroglobulin (Tg) levels, while not specific, were elevated during thyroiditis and normalized with subsequent hypothyroidism in 5 patients with nivolumab-induced thyroiditis [120]. Diffuse increased uptake of the inflammatory tracer 18FDG in the thyroid gland was observed in pembrolizumab-induced thyroiditis [75, 83] and in 2 transiently thyroidotic patients on nivolumab [121]. The differential diagnosis of thyroid dysfunction on checkpoint blockade might be difficult. Hypothyroidism secondary to pituitary failure should be excluded as thyroid substitution therapy could precipitate adrenal failure. A low to normal TSH with low FT4 should prompt the suspicion of hypopituitarism. Euthyroid sick syndrome is also possible in the setting of advanced malignancy. Hyperthyroidism usually results from destructive thyroiditis but cases of Graves’ disease on ipilimumab and tremelimumab have been described [122–124]. Iodine contamination due to frequent radiological investigations and subsequent iodine-induced hyperthyroidism is another possibility in this patient population. Measurement of TSH-receptor stimulating antibodies, thyroid scintigraphy and Doppler flow ultrasonography have their use in distinguishing thyroiditis (low uptake on scintigraphy and low blood flow on ultrasound) from Graves’ disease (high uptake on scan and high blood flow on ultrasound). Of course, recent administration of iodine-containing contrast media could suppress the uptake measured in thyroid scintigraphy [125]. Symptomatic treatment with non-selective beta-blockers could be required. The duration of hyperthyroidism due to thyroiditis is usually short and no additional therapy is required. Antithyroid drugs (e.g., methimazole, propylthiouracil) should be started on suspicion of Graves’ disease or in high-grade hyperthyroidism while awaiting further investigations. Glucocorticosteroids have been used in a patient with thyroid storm [126]. As in hypophysitis, their use is controversial and should only be considered in the most severe cases. Thyroid hormone substitution is usually required for the subsequent phase of hypothyroidism, although a select number of cases were reversible [75, 127].

Why anti-PD-1/PD-L1 therapy favors thyroid dysfunction is not known. The expression of PD-L1 and PD-L2 in normal thyroid tissue has only been analyzed recently [128] and suggests a distinct immunomodulatory role in the thyroid gland. Increased PD-L1 expression has been identified in papillary [129] and anaplastic thyroid carcinoma [130] as a plausible mechanism to evade antitumor immune responses. Polymorphisms in the genes encoding PD-1 and its ligand are related to Graves’ disease, but their association is weak [131, 132]. It remains to be defined whether the subpopulation with preexisting subclinical autoimmune thyroid disease is at any particular risk. The absence of pretreatment thyroid function and antithyroid antibody levels is a limitation in establishing the baseline susceptibility of these patients. Thyroperoxidase antibodies (TPOAb), identified after anti-PD-1 treatment in patients with thyroid dysfunction, have also been identified at baseline in some studies [75, 83, 119, 120]. These findings have only recently been verified in a prospective study, wherein the presence of thyroid autoantibodies seems to increase the risk for thyroid dysfunction [133].

As a side note, treatment with L-T3 may be a better choice than L-T4. The presence of hypothyroidism could have beneficial effects on tumor behavior. As pointed out in a review by Moeller et al. [134], observations in mouse models suggest that hypothyroidism induced by propylthiouracil suppresses tumor growth, whereas T4 administration had the opposite effect [135, 136]. In a murine model of lung carcinoma, treatment with T3 suppressed metastatic tumor growth and prolonged survival while T4 enhanced tumor growth [137]. In humans, hypothyroidism induced by treatment with IL-2 or the tyrosine-kinase inhibitor sunitinib was associated with a prolonged progression-free survival [138, 139] or response to treatment [140]. In an observational study of 23 patients, euthyroid hypothyroxinemia was achieved by the administration of methimazole with the addition of L-T3, while preexisting hypothyroid patients were treated with T3 for T4 replacement. Most of these patients (19 of 23) had a prolonged survival when compared to epidemiological data [141]. It is currently unknown if and how these findings should be implemented in routine clinical practice. There is an urgent need for prospective evaluation of tumor burden with L-T3 compared to L-T4 replacement and to define the optimal level of thyroid hormone substitution balancing the quality of life and the stimulatory effects on tumor growth.

**Diabetes mellitus**

While hypophysitis and thyroid disorders are predominant, checkpoint-blockade associated diabetes mellitus deserves further notice. Its presentation is often severe with fulminating diabetes and ketoacidosis [142]. Its onset ranges from a few weeks [143] up to one year after initiating therapy [144]. The clinical presentation consists of classic symptoms with polyuria, polydipsia, fatigue, weight loss, and dehydration. The C-peptide level is low or undetectable while HbA1c levels are not always very elevated (e.g., < 53 mmol/mol). Diagnostic antibodies found in type 1 diabetes are detected in only half of cases [142, 145]. This could be due to the acute onset of beta cell inflammation. Dysregulation of PD-1 is implied in both checkpoint-blockade and conventional type 1 diabetes, as peripheral CD4+ and regulatory T cells of type 1 diabetes patients show a reduced PD-1 expression [146, 147]. Interestingly, a low CTLA-4 expression on CD4+ and regulatory T cells is also found in type 1 diabetes [148, 149], suggesting that patients receiving CTLA-4 blocking mAb are also susceptible. Hyperrreactivity of the immune system is suspected as some patients experience thyroiditis before the onset of diabetes [143, 145]. This could be in part explained by HLA haplotypes associated with type 1 diabetes and perhaps also with checkpoint-blockade induced diabetes mellitus. The reverse could also be true as one Japanese patient, carrier of an HLA allele resistant to type 1 diabetes, was less severely affected, without ketoacidosis nor complete insulin deficiency [142].

Long-term treatment consists of insulin therapy. The beta-cell destruction induced by checkpoint inhibitors is unlikely to be reversible. However, longer follow-up is required. Screening measures should include routine measurement of blood glucose and HbA1c. Chronic complications should be monitored in those with a survival lasting more than 5 years.
Primary adrenal insufficiency

Checkpoint-blockade associated adrenal insufficiency is a potentially life-threatening complication, caused by hypophysitis or adrenalitis in this patient population. Symptoms are non-specific and include nausea, fatigue, anorexia, abdominal pain, weight loss, hypotension and hypoglycemia. Low early morning serum cortisol is abnormal and the concomitant presence of a high serum ACTH is suggestive of primary adrenal insufficiency, while low serum ACTH is suggestive of secondary adrenal insufficiency. These findings should prompt dynamic testing. The identification of primary adrenal insufficiency can be difficult however by the concomitant use of corticosteroids in the treatment of other irAE. The incidence of combined primary and secondary adrenal insufficiency is also unknown. Primary adrenal insufficiency is probably mediated by adrenalitis. Adrenal autoantibodies were detected in one case of pembrolizumab-induced adrenal failure [150] while bilateral adrenal gland enlargement [151] and increased bilateral 18FDG activity [152] have also been observed. Routine screening of pituitary function tests is advisable before each dosing of immune checkpoint therapy. Patients should be informed about the potential danger of cortisol deficiency. In case of primary adrenal insufficiency, patients should not only receive glucocorticosteroids.

Other endocrine events

Few data are available on the gonadal and parathyroid function during checkpoint blockade therapy. In one retrospective review, 9 ipilimumab-treated patients were identified with low testosterone levels in the absence of hypophysitis [27]. Hypogonadism is difficult to interpret in this patient population because of the severe illness in malignancy and associated secondary hypogonadotropic hypogonadism as well as the use of exogenous corticosteroids for the treatment of irAE. Human fertility could potentially be impaired in the event of hypophysitis leading to persistently low FSH and LH levels. Incidental hypercalcemia with low PTH levels was found in 2 patients [27], perhaps due to hypercalcemia of malignancy. Primary hypoparathyroidism with acute hypocalcemia was described in one case [153], while hypoparathyroidism with no information on serum calcium was detected in one other patient [154].

Study design and limitations

This is a comprehensive analysis of endocrine adverse events on immune checkpoint inhibitors, and the first to include retrospective, prospective, and randomized clinical trials. We chose this approach because adverse events are generally underestimated in randomized clinical trials [155]. The term ‘thyroiditis’ was not routinely used. Patients with painless thyroiditis can be detected both in the phase of hyperthyroidism or hypothyroidism, further complicating correct reporting. Furthermore, the interpretation of thyroid dysfunction depends of the definition used in each individual study. While the Common Terminology Criteria for Adverse Events (CTCAE) are in widespread use [156], they are imprecise for endocrine disorders, as these do not include a description of the hormone levels nor the separate entity of painless thyroiditis. We are aware that our study has its limitations. The analysis was performed at the study level and did not include individual patient data. Human error cannot be excluded in case of missing studies or duplicates. The analyses of the relative risks were not significant for thyroiditis and hypophysitis, and were generally associated with large confidence intervals. This could be due to the smaller number of patients as prospective and retrospective studies were not included for these investigations. Finally, trials were excluded if the endocrine adverse events were not reported and this may overestimate our final results.

Conclusions

Hypophysitis is a frequent endocrine adverse event triggered by anti-CTLA-4 mAb, while thyroid dysfunction is commonly observed with anti-PD-1/PD-L1 therapy. Combined checkpoint blockade shows a remarkably higher incidence. Symptoms are often non-specific and may be related to the disseminated cancer or the use of checkpoint inhibitors itself. A high suspicion of endocrine adverse events is therefore warranted as timely diagnosed and treated, one can avoid life-threatening complications. Our knowledge regarding the pathophysiology in the setting of immune checkpoint inhibitors remains limited, but new data start to unravel the mechanisms of immune dysregulation. This could not only be of value to better understand these adverse events, but also the autoimmune endocrine disorders in general.

Funding

This research did not receive any grant from any funding agency in the public, commercial, or non-profit sector.

Conflict of Interest

The authors declare that they have no conflict of interest.

References


[129] Angell TE, Lechner MG, Jang JK et al. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid 2014; 24: 1385–1393


[134] Moeller LC, Fuhrer D. Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective. Endocr Relat Cancer 2013; 20: R19–R29


[155] Wahab IA, Pratt NL, Kalisch LM et al. The detection of adverse events in randomized clinical trials: Can we really say new medicines are safe? Curr Drug Safety 2013; 8: 104–113